Category:
Carcinomas
Cancer type:
Prostate
Descriptor:
Therapeutic Development
Reference Number:
221
Davies, G. et al. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo.
Int J Cancer 106:348-54 (2003).
PubMed link
Reference Number:
293
Davies G, Watkins G, Mason MD, Jiang WG. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells.
Prostate 60, 317-24 (2004)
PubMed link
Reference Number:
345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival.
Cancer Res.
64, 7962-70 (2004)
PubMed link
Reference Number:
386
Hashem M, Essam T. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer.
J Egypt Natl Canc Inst. 17, 114-20 (2005)
PubMed link
Reference Number:
505
Ye L, Lewis-Russell JM, Davies G, Sanders AJ, Kynaston H, Jiang WG. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Int J Oncol.
30, 521-9 (2007)
PubMed link
Reference Number:
688
Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
Clin Cancer Res.
14, 7385-90 (2008)
PubMed link
Reference Number:
705
Fan S, Meng Q, Laterra JJ, Rosen EM. Role of Src signal transduction pathways in scatter factor-mediated cellular protection.
J Biol Chem.
284, 7561-77 (2009) Epub 2008 Dec 1
PubMed link
